|
Video: What is a Stock Split?
|
|
Inozyme Pharma is a rare disease biopharmaceutical company developing therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. Co.'s product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ectonucleotide pyrophosphatase/phosphodiesterase 1 and adenosine triphosphate-Binding Cassette in the C6 Deficiencies. This pathway is central to the regulation of calcium deposition throughout the body and is further associated with neointimal proliferation, or the overgrowth of smooth muscle cells inside blood vessels. According to our INZY split history records, Inozyme Pharma has had 0 splits. | |
|
Inozyme Pharma (INZY) has 0 splits in our INZY split history database.
Looking at the INZY split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Inozyme Pharma shares, starting with a $10,000 purchase of INZY, presented on a split-history-adjusted basis factoring in the complete INZY split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
07/27/2020 |
|
End date: |
03/27/2024 |
|
Start price/share: |
$18.40 |
|
End price/share: |
$7.39 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-59.84% |
|
Average Annual Total Return: |
-22.02% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$4,015.51 |
|
Years: |
3.67 |
|
|
|
|
|